Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 5/20 | 0.51 |
| ▸ | CTSV | O60911 | 4/20 | 0.51 |
| ▸ | CTSL | P07711 | 3/20 | 0.51 |
| ▸ | CTSK | P43235 | 8/20 | 0.49 |
| ▸ | HPGDS | O60760 | 1/20 | 0.47 |
| ▸ | ACE | P12821 | 1/20 | 0.43 |
| ▸ | DPP4 | P27487 | 1/20 | 0.43 |
| ▸ | PREP | P48147 | 1/20 | 0.43 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.40 |
| ▸ | SRC | P12931 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.39 |
| ▸ | DRD2 | P14416 | 1/20 | 0.39 |
| ▸ | DRD4 | P21917 | 1/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13677290 | 1.00 | CTSS (0.51) | CTSSCTSVCTSLCTSKHPGDS | |
| SCHEMBL5096312 | 1.00 | CTSS (0.51) | CTSSCTSVCTSLCTSKHPGDS | |
| SCHEMBL6803573 | 0.95 | CTSK (0.54) | CTSSCTSVCTSLCTSKHPGDS | |
| SCHEMBL13677168 | 0.95 | CTSK (0.54) | CTSSCTSVCTSLCTSKHPGDS | |
| SCHEMBL4455853 | 0.95 | CTSK (0.54) | CTSSCTSVCTSLCTSKHPGDS | |
| SCHEMBL4452661 | 0.90 | CTSS (0.45) | CTSSCTSVCTSLCTSKHPGDS | |
| SCHEMBL4457925 | 0.90 | CTSS (0.45) | CTSSCTSVCTSLCTSKHPGDS | |
| SCHEMBL7150612 | 0.90 | CTSS (0.45) | CTSSCTSVCTSLCTSKHPGDS | |
| SCHEMBL13677309 | 0.90 | CTSS (0.45) | CTSSCTSVCTSLCTSKHPGDS | |
| SCHEMBL13677310 | 0.89 | CTSS (0.60) | CTSSCTSVCTSLCTSKACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090247471-A1 | INHIBITORS OF CRUZIPAIN AND OTHER CYSTEINE PROTEASES | AMURA THERAPEUTICS LTD. (GB) | 2009-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247471-A1 | INHIBITORS OF CRUZIPAIN AND OTHER CYSTEINE PROTEASES | CPN1, CTRL, CPA1 | CTSS 21/4885CTSV 18/4885CTSL 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.